Phase 1 first-in-human trial in 36 healthy adults: oral SNIPR001, a CRISPR-Cas-armed phage cocktail against E coli, caused only mild or moderate adverse events, no more than placebo (p=0.94); its reduction of stool E coli (secondary) was not significant.
RCTn = 36
Petersen et al. Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study